JOHN FINDLEY: Open Payments
NPI 1891777504 · BOSTON, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$331 in 13 payments from 8 companies in 2025. Trend: 2023 $136 · 2024 $139 · 2025 $331
Food & beverage: $331
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $67 |
| Otsuka America Pharmaceutical, Inc. | 2 | $57 |
| E.R. Squibb & Sons, L.L.C. | 2 | $55 |
| Janssen Pharmaceuticals, Inc | 2 | $45 |
| ABBVIE INC. | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 1 | $27 |
| Alkermes, Inc. | 1 | $26 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $19 |
Products named: CAPLYTA, COBENFY, INVEGA SUSTENNA, VRAYLAR, REXULTI, UZEDY, ARISTADA, ABILIFY MAINTENA.
Industry payments across MA — which companies pay providers there.
